Clinical trials: Protozoan Infections
Malaria
PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.
- Trial name
- NCT02601716
- Testing
- PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Falciparum
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis
This study will assess the superior protective immunity of the combination of chloroquine and azithromycin prophylaxis under Chemoprophylaxis Sporozoites (CPS) immunization versus a standard chloroquine prophylactic regimen.
- Trial name
- MMV (NCT01783340)
- Testing
- Azithromycin capsules, Immunization with falciparum
- Where
- Netherlands
- Volunteers
- healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
Impact of Enhanced Health Facility Care in Uganda
The investigators propose to assess whether an intervention to build capacity and improve delivery of drugs and diagnostics at government-run health facilities improves the health of children and quality of care delivered, as…
- Trial name
- NCT01024426
- Testing
- Enhanced health facility-based care, Standard care
- Where
- Uganda
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Uganda Malaria Surveillance Project
Malaria, Mass Drug Administration
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Plasmodium vivax has become the predominant species in the Greater Mekong Subregion and is a major challenge for regional malaria elimination.
- Conditions
- Malaria, Mass Drug Administration, Myanmar, Plasmodium Vivax
- Trial name
- NCT06392152
- Testing
- Focal Mass Drug Administration with Primaquine
- Where
- Burma
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- Pyae Linn Aung
Malaria
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Background: Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away.
- Trial name
- NCT02471378
- Where
- Mali
- Volunteers
- 7,476 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Vivax Malaria
Papua New Guinean Duffy Negativity And Vivax Malar
The purpose of this study is to learn more about vivax malaria in very young children, how the growth of children is affected by malaria infections, and how inherited traits protect children from getting malaria.
- Trial name
- NCT00138489
- Where
- Papua New Guinea
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali
Background: P. falciparum, one of the most virulent forms of malaria, causes more than 300 million episodes of malaria and 1 million deaths each year.
- Trial name
- NCT00863408
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
This is a single centre, randomized, placebo-controlled phase 1/2 study comparing two malaria vaccine candidates. The first vaccine candidate PfSPZ-CVac (Plasmodium falciparum sporozoites (PfSPZ) challenge administered with a…
- Trial name
- NCT05441410
- Testing
- Pyronaridine Tetraphosphate, Artesunate Drug Combination, PfSPZ Challenge (NF54), MVA ME-TRAP
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Malaria
Perennial Malaria Chemoprevention (PMC) Effect Study
The Malaria Consortium Nigeria (MC) will coordinate a trial of PMC in Osun State, Nigeria with strategic support from the National Malaria Elimination Programme of the Government of Nigeria (NMEP) and financial support from the…
- Trial name
- PMCEffect (NCT06155448)
- Testing
- Perennial Malaria Chemoprevention effect
- Where
- Nigeria
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Malaria Consortium
Alpha and Beta Thalassemia, Sickle Cell Disease
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Background: Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders.
- Conditions
- Alpha and Beta Thalassemia, Sickle Cell Disease, Malaria, Human Physiology
- Trial name
- NCT03937817
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis
Single center, randomized, placebo-controlled, double-blinded trial using PfSPZ Challenge (NF54) under A/P chemoprophylaxis for immunization and PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) for repeat CHMI.
- Trial name
- NCT02858817
- Testing
- atovaquone/proguanil 250mg/100mg (A/P), PfSPZ Challenge (NF54), NaCl 0,9%
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Malaria
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
This randomized, double-blind, placebo-controlled, Phase 1 trial will enroll up to 22 malaria-naïve, adult participants to test safety, tolerability, immunogenicity, and efficacy of the genetically attenuated Plasmodium…
- Trial name
- NCT06735209
- Testing
- PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
- Trial name
- DNA-Ad (NCT00870987)
- Testing
- DNA vaccine prime, adenovirus type 5 vaccine boost
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Fever, Malaria
Use of Malaria Rapid Diagnostic Tests as a Decision Aid for the Management of Fever by International Travelers
This study is part of a larger prospective cohort study (JOKA), designed to study the incidence and etiological spectrum of febrile illness occurring during a travel to the tropics, as well as clinical course, care, treatment and…
- Trial name
- JOKA-I (NCT02900079)
- Testing
- rapid diagnostic test for malaria antigen
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Chagas Disease
Selenium Treatment and Chagasic Cardiopathy (STCC)
Background: Chagasic myocardiopathy caused by the protozoa Trypanosoma cruzi has been the principal cause of cardiac death in Latin America.
- Trial name
- STCC (NCT00875173)
- Testing
- Selenium
- Where
- Brazil
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Malaria
Weekly Dosing of Malarone ® for Prevention of Malaria
The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
- Trial name
- MALWEEK (NCT00984256)
- Testing
- Atovaquone Proguanil, Procedure - malaria challenge
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Falciparum
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
The primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 µg dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel® in healthy European adults not previously exposed to the parasite…
- Trial name
- AMA1-DiCo (NCT02014727)
- Testing
- Group A1 : 50µg AMA1-DiCo + Alhydrogel, Group A2 : 50 µg AMA1-DiCo+ GLA-SE
- Where
- 2 sites in Burkina Faso, France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Malaria
Stimulating Private Sector Malaria Control
Preliminary evidence from ongoing research provides strong indications that protecting farmers from malaria would be profitable for outgrowing agribusinesses in sub-Saharan Africa.
- Trial name
- Outgrowers (NCT01397851)
- Testing
- Insecticide-treated net (BASF Incerceptor)
- Where
- Zambia
- Volunteers
- 81,597 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria
Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali
There are about 300-500 million cases of malaria worldwide each year, with 2-3 million deaths. Plasmodium falciparum, one of four types of malaria, is responsible for most of these deaths.
- Trial name
- NCT00341783
- Where
- United States
- Volunteers
- 515 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria Prophylaxis
Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates
Malaria represents a major public health concern in sub-Sahara Africa. Seasonal malaria chemoprevention (SMC) is one of the largest preventive measures.
- Conditions
- Malaria, Malaria Prophylaxis, Mass Testing and Treatment
- Trial name
- SMC-RST (NCT04816461)
- Testing
- Amodiaquine Sulfadoxine-Pyrimethamin administration, Dihydroartemisinin-Piperaquine, Standard HRP2-RDT
- Where
- Burkina Faso
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche en Sciences de la Sante, Burkina Faso